Obesity is chronic. Multi-year planning is appropriate. Here's the math.
About this article
Reviewed byDr. J. Bottoni, M.D.
RoleEditor-in-Chief, Medicine
First publishedMay 20, 2026
Last reviewedMay 20, 2026
Page typeIn-depth editorial guide
Sources15+ cited sources
Predictable cash-pay (NexLife 12-mo plan)
| Year | Sema | Tirz |
|---|---|---|
| 1 | $1,740 | $2,232 |
| 3 | $5,220 | $6,696 |
| 5 | $8,700 | $11,160 |
| 10 | $17,400 | $22,320 |
vs untreated obesity-related healthcare cost
Untreated obesity-related healthcare costs (CV events, T2D, OSA, MASH, joint replacements) often exceed GLP-1 therapy cost over 10+ year horizons. The SELECT trial supports this premise for CV outcomes specifically.
Considering price changes
Branded GLP-1 prices: history of increases. Cash-pay compounded: NexLife flat-rate held through 2024–2026. Multi-year contracts (12-mo plans) lock pricing.
Budget categories
- Medication (NexLife $145–$215/mo)
- Annual labs (if not included in your plan, $50–$200/yr)
- Specialist visits (if needed for comorbidities)
- Lifestyle support (gym, protein supplements, etc.)